Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Gullotta Tina	2. Date of Event Requiring Statement (MM/DD/YYYY) 4/28/2020	3. Issuer Name and Ticker or Trading Symbol SUNESIS PHARMACEUTICALS INC [SNSS]
(Last)        (First)        (Middle) SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                          _____ 10% Owner ___X___ Officer (give title below)        _____ Other (specify below) VP, Finance /
(Street) SOUTH SAN FRANCISCO, CA 94080       (City)              (State)              (Zip)	5. If Amendment, Date Original Filed(MM/DD/YYYY)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	14500	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	8/31/2028	Common Stock	40000	$2.18	D
Stock Option (Right to Buy)	(2)	12/31/2028	Common Stock	8611	$0.4157	D
Stock Option (Right to Buy)	(3)	3/29/2029	Common Stock	10000	$1.215	D
Stock Option (Right to Buy)	(4)	3/31/2030	Common Stock	70000	$0.4149	D

Explanation of Responses:
(1)	One fourth (1/4th) of the shares shall vest one (1) year from the Vesting Commencement Date of August 31, 2018. Thereafter, one forty-eighth (1/48th) of the shares granted shall vest monthly over the next thirty-six (36) months.
(2)	One fourth (1/4th) of the shares shall vest one (1) year from the Vesting Commencement Date of December 31, 2018. Thereafter, one forty-eighth (1/48th) of the shares granted shall vest monthly over the next thirty-six (36) months.
(3)	One fourth (1/4th) of the shares shall vest one (1) year from the Vesting Commencement Date of March 29, 2019. Thereafter, one forty-eighth (1/48th) of the shares granted shall vest monthly over the next thirty-six (36) months.
(4)	One fourth (1/4th) of the shares shall vest one (1) year from the Vesting Commencement Date of March 31, 2020. Thereafter, one forty-eighth (1/48th) of the shares granted shall vest monthly over the next thirty-six (36) months

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Gullotta Tina SUNESIS PHARMACEUTICALS, INC. 395 OYSTER POINT BOULEVARD, SUITE 400 SOUTH SAN FRANCISCO, CA 94080			VP, Finance

Signatures
/s/ Tina Gullotta		5/5/2020
**Signature of Reporting Person		Date